{"id":"W4402938149","doi":"10.1177/17588359241277656","title":"Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; McGill University Health Centre","funders":"Eisai; Clovis Oncology; Incyte; Novocure; Regeneron Pharmaceuticals; Seagen; Gilead Sciences; Genentech; Mersana Therapeutics; AstraZeneca; Pfizer","keywords":"Medicine; Placebo; Adverse effect; Common Terminology Criteria for Adverse Events; Internal medicine; Endometrial cancer; Randomized controlled trial; Population; Carboplatin; Phases of clinical research; Chemotherapy; Oncology; Surgery; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002584937,0.000982387,0.002968586,0.0003501444,0.0003582581,0.0009006059,0.0007390322,0.001250782,0.003600025],"category_scores_gemma":[0.001831195,0.0005338361,0.001738457,0.0003810416,0.001009859,0.0006804856,0.0003509605,0.002168449,0.0005222718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005471248,"about_ca_system_score_gemma":0.0012445,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003648734,"about_ca_topic_score_gemma":0.001108018,"domain_scores_codex":[0.9989129,0.0007108841,0.0000683765,0.0001569687,0.00008113547,0.00006977446],"domain_scores_gemma":[0.9991692,0.000175111,0.0003335125,0.00006298652,0.00005868783,0.0002004087],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9667973,0.005114403,0.001051553,0.001112768,0.001567831,0.00003884614,0.00005089224,0.0003216553,0.004169432,0.000070778,0.000638073,0.0190664],"study_design_scores_gemma":[0.9162266,0.08058577,0.001570768,0.0000312942,0.0004851272,0.00003774748,0.00001057146,0.0002305461,0.0002835771,0.00005223688,0.0004783917,0.000007327487],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800196,0.01103985,0.0007834628,0.0006513154,0.0004120483,0.004847854,0.0006792962,0.0001231515,0.001443461],"genre_scores_gemma":[0.9855353,0.004245328,0.001850285,0.0009949788,0.0004481846,0.004741709,0.000831144,0.00002319212,0.001329854],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003600025,"threshold_uncertainty_score":0.01367062,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01383054762002973,"score_gpt":0.3580351310890937,"score_spread":0.344204583469064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}